Document Type : Original Article
Authors
- Danesh Hassani 1
- Mohammad Mehdi Amiri 1
- Faezeh Maghsood 1
- Vahid Salimi 2
- Gholam Ali Kardar 3
- Omid Barati 4
- Seyed Mohammad Reza Hashemian 5
- Mahmood Jeddi-Tehrani 6
- Amir-Hassan Zarnani 1
- Fazel Shokri 1
1 Department of Immunology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran
2 Department of Virology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran
3 Immunology Asthma & Allergy Research Institute, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran
4 Health Human Resources Research Center, School of Management and Medical Informatics, Shiraz University of Medical Sciences, Shiraz, Iran
5 Chronic Respiratory Diseases Research Center (CRDRC), National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran
6 Monoclonal Antibody Research Center, Avicenna Research Institute, ACECR, Tehran, Iran
Abstract
Background: Incidence and severity of SARS-CoV2 infection are significantly lower in children and teenagers proposing that certain vaccines, routinely administered to neonates and children may provide cross-protection against this emerging infection. Objective: To assess the cross-protection induced by prior measles, mumps and rubella (MMR) vaccinations against COVID-19. Methods: The antibody responses to MMR and tetanus vaccines were determined in 53 patients affected with SARS-CoV2 infection and 52 age-matched healthy subjects. Serum levels of antibodies specific for NP and RBD of SARS-CoV2 were also determined in both groups of subjects with ELISA. Results: Our results revealed significant differences in anti-NP (p <0.0001) and anti-RBD (p <0.0001) IgG levels between patients and healthy controls. While the levels of rubella- and mumps specific IgG were not different in the two groups of subjects, measles-specific IgG was significantly higher in patients (p <0.01). The serum titer of anti-tetanus antibody, however, was significantly lower in patients compared to healthy individuals (p <0.01). Conclusion: Our findings suggest that measles vaccination triggers those B cells cross-reactive with SARS-CoV2 antigens leading to the production of increased levels of measles-specific antibody.
Keywords
)